CGT Research Outlook Technology Report 2024: Capacity and Capability Expansion for CDMOs, Technology Licensing Partnerships, Shift Towards CGT Development for Chronic Diseases
30 août 2024 06h46 HE
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "CGT Research Outlook and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report covers the...
Gene Therapy R&D Market Report 2024-2034 - Gene Therapy Resurgence Fuelled by Groundbreaking Advancements, Soaring Investments and a Promising Pipeline Reshaping Medicine's Future
01 juil. 2024 10h10 HE
|
Research and Markets
Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for Gene Therapy R&D Market is...
Adeno-associated Virus Gene Therapy Market Report 2024-2034: Epidemiology, Industry Trends and Forecasts
21 juin 2024 06h05 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Adeno-associated Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been...
Exosome Therapeutics Pipeline research 2024
19 juin 2024 07h45 HE
|
Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Exosomes - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.An array of drugs is currently moving through various...
Genomics Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 948 Agreements Signed Since 2016
07 mai 2024 07h14 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Genomic Collaboration and Licensing...
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...
Viral Vector and Plasmid DNA Technologies Market Outlook 2024-2028: Innovations, Technological Advances and Product Launches from Leading Companies
05 avr. 2024 04h02 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for...
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene et NEC prévoient de lancer, en 2024, une extension de l’étude randomisée de Phase I en essai randomisé de phase I/II pour continuer à démontrer le potentiel de TG4050 comme traitement...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...